Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...
Clinician-led engagement outperforms non-clinical call-center models, with “nurse ambassador” programs enabling escalation, ...
Medication nonadherence is common and costly, with higher rates in biologics for autoimmune disease (28–52%), reflecting intertwined barriers spanning beliefs, side effects, affordability, and ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains how real-time data generated through direct-to-patient models are shaping pharma's commercial decisions. Direct-to-patient (DTP) ...
Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...
Only 18% of payers report using RWE in coverage decisions despite 80% expressing demand, reflecting a market access disconnect driven primarily by interpretability and usability barriers. Payers’ ...
Active shortages reached 323 in Q1 2024, with persistent durations and major chemotherapy impact; the burden includes rationing, delayed/canceled care, and substantial hospital labor costs. Generic ...
Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply ...
The pharmaceutical industry has witnessed a resurgence of mergers and acquisitions (M&As) as companies seek to gain a competitive edge, accelerate innovation, and drive growth. By consolidating ...
This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results